Good morning, everyone. Welcome to Medical Facilities Corporation's 2023 second quarter earnings call. After management's remarks, this call will include a question and answer session in which qualified equity analysts will be permitted to ask questions. Before turning the call over to management, listeners are reminded that today's call may contain forward-looking statements within the meaning of the safe harbor provisions of Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties. Undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. For additional information, please co-consult the MD&A for this quarter, the Risk Factors section of the Annual Information Form, Medical Facilities other filings with Canadian Securities Administrators. Medical Facilities does not undertake to update any forward-looking statements. Such statements speak only as of the date made. I would now like to turn the meeting over to Mr. Jason Redman, President and CEO of Medical Facilities. Please go ahead. Thank you, Operator. Good morning, and welcome to our second quarter earnings call. With me on the call is our Chief Financial Officer, David Watson. Earlier this morning, we reported our Q2 results. Our news release, financial statements, and MD&A may be accessed through our website, the medicalfacilitiescorp.ca, and have also been filed with SEDAR. We had a solid second quarter. Our facilities service revenue was up 7.2%. Our surgical volumes were up 1% when excluding the MFC Nueterra ASCs, and our income from operations and EBITDA were up 8.3% and 9.2%, respectively, when excluding non-controllable non-cash charges at the corporate level related to share-based compensation plans. While the charge in the quarter was nominal, the corresponding expense reversal last year boosted our income from operations and EBITDA by approximately $2 million. These non-operational charges match the actual performance of our business. Excluding them provides a more accurate assessment of our ability to generate cash flow and deliver returns to our shareholders. During the quarter, we used our strong cash flow to pay down debt and returned another $1.9 million to shareholders through share repurchases. We also substantially completed our overhead cost reduction plan, which we first announced, along with our change in corporate strategy last September. We benefited from our cost-saving initiatives during the quarter. We are pleased to say that we have now reduced corporate costs by an annual run rate of approximately $5 million. Subsequent to quarter end, we completed the sale of City Place Surgery Center and Miracle Hills ASC and sold our non-controlling ownership interest in St. Luke's. The transactions following quarter end provided aggregate net proceeds of $2.3 million. The buyer of St. Luke's also assumed debt of $5 million, and the lender released MFC from his pro rata guarantee. Finally, I want to give a quick shout-out to our four surgical hospitals, each of which received five-star ratings for staff responsiveness based on publicly reported measures from the annual HCAHPS survey data from CMS. With that, I'd like to turn the call over to David to review our financial results. David? Thank you, Jason, good morning, everyone. I would like to start by reminding everyone that all dollar amounts that follow are in US dollars unless stated otherwise. Facility service revenue for the quarter increased 7.2% to $109.5 million, largely due to case and payer mix, as well as the impact of Sioux Falls moving its anesthesia service and related billing in-house in the current year. Overall, surgical case volumes were down 5%. However, as Jason mentioned earlier, when excluding the MFC Nueterra ASCs, volumes were up 1%. Excluding the MFC Nueterra ASCs, observation cases increased by 30.2%, while inpatient cases were down 10.8% and outpatient cases were down 1.4%. Our operating expenses increased by $7.9 million, or 9.1% to $93.9 million. Consolidated salaries and benefits were up by $1.3 million, or 4.3%, primarily due to the impact of Sioux Falls moving its anesthesia service and related billing in-house in the current year, higher clinical and non-clinical salaries and wages, and separation costs for our former Chief Development Officer. Clinical and non-clinical salaries and wages were subject to annual increases, full-time equivalent increases, and market wage pressures. The higher salaries and benefits were partly offset by cost saving initiatives at corporate level to the tune of $1.2 million, and the forfeiture of stock options relating to the former Chief Development Officer in the current year. Consolidated drugs and supplies were up $2.9 million or 8.6%, largely due to an increase in spine and higher acuity orthopedic cases, partly offset by higher vendor rebates and the closure of clinical operations at Eastwind Surgery Center back in May. Consolidated G&A increased by $3 million, or 19.4%. Swing was mainly due to non-controllable corporate level costs related to share-based compensation plans, driven by an increase in our share price in the quarter versus the significant decrease in corresponding $2 million expense reversal in the same period last year. While we also had increases in billing fees, contracted services, and facility-related expenses, as well as costs pertaining to Sioux Falls' Accountable Care Organization, these were partly offset by cost savings of $500,000 at the corporate level.... Income from operations was $15.6 million, representing an increase of 8.3% when excluding the non-cash charges Jason and I highlighted. EBITDA for the quarter was $21.2 million, which was an increase of 9.2% when excluding the same charges. Finance costs for the quarter increased $16.7 million, due primarily to the $16.4 million increase in non-cash costs related to the change in value of the exchangeable interest liability. Like share-based compensation, the value of the exchangeable interest liability fluctuates based on the share price, which resulted in a $14.4 million reversal of expense in the prior year. In the quarter, we generated cash available for distribution totaling CAD 6.6 million, resulting in a payout ratio of 30.8%. Looking at our NCIB, during the quarter, we purchased 316,100 of our common shares for a total consideration of $1.9 million. For the first six months of the year, we purchased 734,000 shares, returning $4.5 million to our shareholders. We also used our strong operating cash flow and cash balance to repay $9 million on our corporate credit facility during the quarter, bringing the balance down to $27 million. This contributed to a decrease in cash and equivalents at quarter end. At the end of the quarter, we had consolidated net working capital of $22.3 million, including $27.9 million of cash and equivalents. For comparison, at the end of 2022, we had working capital of $32.5 million, including cash and equivalents of $34.9 million. Inclusive of lease liabilities, our net debt to equity remains low at 0.87 times as compared to 0.94 at December 31, 2022. This concludes our prepared remarks. We would now like to open up the call for questions. Operator? Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star followed by one on your touchtone phone. You will hear a three-tone prompt acknowledging your request, and your questions will be polled in the order they are received. Should you wish to decline from the polling process, please press star followed by two. If you are using a speakerphone, please lift the handset before pressing any keys. One moment, please, for your first question. Your first question comes from Andre Bodo, National Bank. Andre, please go ahead. Hi, good morning. It's Andre Bodo sitting in for Andre Bodo. My first question pertains to the remaining ASCs. What's your plan for them, given that they're such a small part of the business now? Yeah. Let me address that. I mean, the last remaining ASC that we have with Nueterra is in the process of being dealt with now. The other ASC, we have Newport. No decision has been made with respect to that yet. Okay. Do you expect beyond ASCs in terms of more asset sales? Sorry, can you repeat your question, please? Beyond the ASCs in terms of more asset sales? Yeah, that's, no decision's been made, yet with respect to any disposition of further assets. Proceeds. What is your plan for them? Again, the, any proceeds, the, the board has not made any decision with respect to allocation of proceeds yet. My final question, do you see the 2024 Medicare budget increasing, increase affecting, DRGs, specific mix at all? Overall, I think the 2024 increases are roughly a net increase of about 3%. Now, that's overall and not procedure speci-specific. I don't have the detail yet on how it applies to our specific specialties. Okay, great. Thank you. Thank you. Ladies and gentlemen, as a reminder, should you have a question, please press star one on your touchtone phone. Your next question comes from Sahil Dhingra, RBC. Sahil, please go ahead. Hi, good morning. This is Sahil filling in for Douglas Miehm. Thank you for taking our questions. My first question is: What was the contribution of the assets that have been disposed of and that were disposed of after the quarter? Yeah. Hi, Sahil. The, the contribution was, was really immaterial. You know, as we've, you know, noted, you know, we saw a decrease in case volume at the, at the MFC Nueterra ASCs, and the corresponding impact of that on, in the earnings is what you'd expect. Okay. My second question is: Going forward, how are you going to prioritize between debt repayments and dividend increase or share buybacks? Yeah. The, the allocation of capital is something that the board is, is constantly looking at. We're aware obviously there's, there's various methods that, that we can use to deploy that capital, but no decision's been made yet. Okay. In terms of inflationary pressures, are you seeing any normalization there, if you have any updated color on those? Yeah, and you know, overall, I would say, on the labor side, we're seeing less need for, you know, special payments, recruiting bonuses, that type of thing. Like much of the in- industry, that's beginning to normalize. That said, we do continue to see, you know, the types of, increases that, you're seeing across most, most, labor markets. On the expense side, we, on the other expenses, drug supplies, that kind of thing, we do, you know, benefit from having a, a group purchasing plan in place. We, you know, are experiencing, you know, the same inflationary pressures that everyone else is. Okay. Are you seeing any pressures from new competition that has come up in some of the markets? No, not, not currently. Nothing that's been material to our operations. Okay, the final question is, what explains the year-over-year decline in cash available for distribution, even though EBITDA was broadly similar? Yeah, if you look at the calculation of cash available for distribution, the prior year includes the $2 million reversal of the impact on share-based compensation. If you were to remove that, it changed the picture a bit. Okay, great. Thank you so much for taking our questions. Sure. Thank you, Operator. Thank you. Ladies and gentlemen, as a final reminder, should you have a question, please press star one on your touch-tone phone. There are no further questions at this time. Please proceed. Thank you, Operator. I'd like to thank everyone for taking the time this morning. We look forward to speaking with you again in November. Thank you. Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.